Abstract
Background: Approximately 40% of people under 30 and over 90% of people 55 or older suffer from moderate-to-severe levels of degenerative intervertebral disc (IVD) disease in their lumbar spines. Surgical treatments, including discectomy or fusion, are effective; however, several complications have been reported, so new treatments are necessary. Apoptosis may be important in IVD degeneration because suppressing cell apoptosis inside the IVD inhibits degeneration. Caspase-3, the primary effector of apoptosis, may be a key treatment target. Methods: To investigate whether the different pathological mechanisms in injury- (IRD) and age-related IVD degeneration (ARD) affect the response to caspase-3 deletion and whether long term inhibition of caspase-3 results in tumorigenesis, we analyzed the role of the caspase-3 in IRD and ARD models using caspase-3 knockout (Casp-3 KO) mice. Findings: Casp-3 KO delayed IVD degeneration in the injury-induced model but accelerated it in the age-induced model. Our results suggest that this is due to different pathological mechanisms of these two types of IVD degeneration. Specifically, we found that apoptosis is the primary driving factor in injury-related IVD degeneration, but cellular senescence, but not apoptosis, seems to be the primary driving factor in age-related IVD degeneration. Interpretation: The present results suggest that short-term caspase-3 inhibition could be used in the treatment of IRD and provide further evidence that anti-apoptotic treatment of IVD degeneration represents a new avenue of investigation for treating spinal trauma. Funding Statement: Grant-in-Aid for the Ministry of Education, Culture, Sports, Science, and Technology of Japan (26670651 and 17K16669). Declaration of Interests: The authors state: There are no competing interests. Ethics Approval Statement: All animal procedures in this study were approved by the Institutional Animal Care and Use Committee of Hokkaido University. All procedures were carried out in accordance with the approved guidelines.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.